Open Access

Validation of Novaprep® HQ+ liquid-based cytology medium for high-risk human papillomavirus detection by hc2

  • David Guenat1, 2, 3,
  • Sophie Launay1, 3,
  • Didier Riethmuller1, 2, 3,
  • Christiane Mougin1, 2, 3 and
  • Jean-Luc Prétet1, 2, 3, 4, 5Email author
Infectious Agents and Cancer201611:41

https://doi.org/10.1186/s13027-016-0092-7

Received: 4 May 2016

Accepted: 28 June 2016

Published: 17 August 2016

Abstract

Background

Preanalytical conditions determine the reliability and validity of bioassays. Therefore, the analytic performances of biological tests need to be determined when preanalytical steps differ from those recommended by the manufacturer. The objective of the study was to assess the analytic performance of the hc2 test for the detection of high-risk HPV DNA from cells stored in the new Novaprep® HQ+ medium.

Methods

Repeatability, reproducibility, method comparison and stability (-20 °C, +4 °C, +20 °C and +40 °C up to six months) were evaluated from HPV16 and HPV18 positive cell lines diluted in the Novaprep® HQ+ medium and the reference Specimen Transport Medium (STM). A series of cervical samples with atypical squamous cells of undetermined significance (ASC-US) cytology and stored in the Novaprep® HQ+ medium was also tested.

Results

Coefficients of variation for repeatability and reproducibility were less than 8 %. Method comparison showed perfect agreement in hc2 results when the HPV-positive cells were diluted in HQ+ and reference media. Stability experiments demonstrated that the storage conditions did not alter the hc2 test results. Furthermore, clinical samples were adequately preserved for hc2 testing.

Conclusions

Overall, our data show that the new Novaprep HQ+ medium is suitable for high-risk HPV testing by hc2.

Keywords

Papillomavirus Liquid based cytology HPV testing Validation Hybrid capture 2

Background

According to Arbyn’s meta-analysis, the sensitivity of both conventional and liquid-based cytology (LBC) remains low (below 60 %) for the detection of high grade squamous intraepithelial lesions (HSIL) of the cervix [1]. High-risk human papillomavirus (hrHPV) testing has been proposed to overcome the limits of cervical cytology for the triage of women with atypical squamous cells of undetermined significance (ASC-US) cytology [2]. Moreover, alone or in combination with cytology, hrHPV testing allows screening of HSIL or cancers with high sensitivity and negative predictive value [36]. In this way, introducing HPV testing as a primary screening test may improve the safety and cost-effectiveness of cervical cancer screening [4, 710].

Among the most reliable HPV DNA tests, the hybrid capture 2 test (hc2) is a nucleic acid hybridization assay with signal amplification. This technique has been validated by the manufacturer using the Specimen Transport Medium (STM) (Qiagen, Hilden, Germany), the ThinPrep Pap Test (Hologic, Marlborough, MA, USA) and the BD SurePath™ liquid-based Pap test (BD, Franklin Lakes, NJ, USA) to collect cervical cells. In 2010, we conducted a clinical study to assess the suitability of the LBC Novaprep® Vial Test system (Novacyt, Vélizy-Villacoublay, France) for hrHPV DNA detection in cervical samples using the hc2 test. Very high agreement for hrHPV DNA detection was found between two consecutive cervical samples deposited in the Novaprep® Vial Test and in the reference medium STM (Qiagen) [11]. Since this study, the fixative composition of the Novaprep® system has been slightly modified and the product is now called Novaprep® HQ+ Orange. The objective of this study was to assess whether the modifications of the Novaprep LBC medium impact the performance of the hc2 assay to detect hrHPV DNA. A comprehensive evaluation of repeatability, reproducibility, method comparison and stability was conducted to identify potential sources of variation and interference.

Methods

Cell lines

The human Ca Ski (HVP16, 400 to 600 copies per cell) and SiHa (HVP16, 1 to 2 copies per cell) cell lines, the HeLa (HPV18, 20 to 40 copies per cell) cell line and the HPV negative C33-A cell line were obtained from ATCC (Manassas, VA, USA) and routinely tested for the presence of HPV in our laboratory. Ca Ski and SiHa cells were maintained at 37 °C (5 % CO2) in complete RPMI or DMEM respectively (Lonza, Levallois-Perret, France) supplemented with 10 % fetal bovine serum (FBS; Lonza), 5x104 U/L penicillin/streptomycin (Lonza) and 2 mM L-glutamine (Lonza). HeLa and C33-A cells were grown in complete EMEM (Lonza) supplemented with 10 % FBS, 5x104 U/L penicillin/streptomycin and 2 mM L-glutamine.

HPV positive and HPV negative cells were diluted at indicated concentrations in the STM (Digene/Qiagen, Courtaboeuf, France) as reference medium and in the Novaprep® HQ+ Orange medium (Novacyt, Vélizy-Villacoublay, France), an alcohol-based fixative primarily dedicated to liquid-based cytology. Because pretreatment of viscous samples with dithiothreitol (DTT), a mucolytic agent, may be recommended to provide mucus-free single-cell suspensions, Novacyt also provided the Novaprep® HQ+ orange containing 0.03 % DTT. For convenience, the Novaprep® HQ+ medium without DTT will be referred to as HQ + A and the Novaprep® HQ+ medium with DTT will be referred to as HQ + B.

Cervical samples

Three hundred and twenty two consecutive samples collected at the endocervical-ectocervical junction with a cytobrush, conserved in Novaprep® HQ+ Orange medium and with an ASC-US diagnosis were routinely tested for hrHPV with the Digene hc2 High-Risk HPV DNA Test (Qiagen). All samples were stored in a biobank approved by the local ethics committee (Comité de Protection des Personnes Est II), and for which a declaration of collection and storage of human samples for research use has been lodged with the French Ministry of Higher Education and Research (Ministère de l’Enseignement Supérieur et de la Recherche) (declaration number DC-2014-2086).

Repeatability and reproducibility

Repeatability of hc2 testing was assessed by calculating the mean, the standard deviation (SD), and the coefficient of variation (CV) of relative light units/cutoff (RLU/CO) from 14 replicates prepared extemporaneously with medium HQ + A and medium HQ + B. This assessment was conducted using three concentration levels of HPV16 + cells (corresponding to 1.25x105 and 1.25x106 SiHa cells and 6.25x104 Ca Ski cells per mL) and HPV18 + cells (corresponding to 3.12x104, 6.25x104 and 6.25x105 HeLa cells per mL) expected to give clinically relevant RLU/CO values. Assessment of the reproducibility of hc2 testing was conducted using three different batches of HQ + A and HQ + B media (namely HQ+ A1; HQ+ A2; HQ+ A3; HQ+ B1; HQ+ B2; HQ+ B3). Fourteen replicates of 1.25x105 SiHa cells/mL were prepared extemporaneously with the different batches of media. The mean, SD and CV of RLU/CO were calculated from 42 replicates for each media.

Method comparison

Method comparison was conducted using six HPV16 positive samples and 6 HPV negative samples prepared extemporaneously with the reference medium STM and with HQ + A and HQ + B media. HPV positive samples consisted of 5x104 and 2.5x104 Ca Ski cells/mL and 2.5x106, 1.25x106, 6x105 and 3x105 SiHa cells/mL. The HPV negative C33-A cells were used to obtain 2.5x106, 1.25x106 and 6x105, 3x105, 1.5x105 and 0 cells/mL. Each sample was analyzed in duplicate. The sensitivity and specificity of hrHPV detection were calculated for each medium.

Stability

For stability, the effect of time and temperature of storage was analyzed using freshly prepared SiHa cells (1.7x105 cells/mL) stored in the three batches of HQ + A and HQ + B media up to 6 months at 18 to 25 °C (hc2 analysis was performed at weeks 0, 2, 4, 6, 8, 10, 12, 16, 24 and 28) and at -15 to -30 °C (hc2 analysis at weeks 2, 4 and 28) and up to 3 months at 2 to 8 and 40 °C (hc2 analysis at weeks 2, 4, 6, 8, 10, 12 and 16).

Human papillomavirus DNA detection

High-Risk HPV DNA testing was performed with the hc2 High-Risk HPV DNA Test® (Qiagen/Digene) according to the manufacturer’s instructions. For the denaturation step, the protocol dedicated to samples collected in the PreservCyt solution was applied to cellular samples (cell lines or cervical samples) collected in Novaprep® HQ+ Orange media without and with DTT. Briefly, 0.1 volume of sample conversion buffer (Qiagen) was added to each tube containing 1 mL of HPV positive or HPV negative cells collected and stored in Novaprep®HQ+ orange. After vortexing, cells were centrifuged at 2900 g for 15 min (±2 min) and supernatant was carefully decanted. Then 300 μL (1 mL for the method comparison) of Specimen Transport Medium/Denaturing Reagent mixture (in a 2:1 ratio) was added to cell pellets that were resuspended by vortexing. The denaturation step was conducted for 15 min at 65 °C, then specimens were vortexed and incubated at 65 °C for another 30 min. A 75 μL aliquot of denatured samples was processed for hybridization as recommended by the manufacturer. All experiments were conducted with the same batch of hc2 High-Risk HPV DNA Test®.

Results

Means, SD and CV for repeatability and reproducibility are presented in Tables 1 and 2 respectively. The CV for repeatability varied from 2.4 to 7.6 % according to the media tested and the genotype detected. As regards reproducibility, the CV were in the same range as those obtained for repeatability, namely 6 % for the three batches of medium HQ + A and 8 % for the three batches of medium HQ + B. As a whole, these CV were very satisfactory and were lower than the CV proposed by the manufacturer for their internal Quality Control (25 %).
Table 1

Repeatability analysis of HPV16 and HPV18 DNA by hc2

 

Mean RLU/CO

SD

CV%

HPV16 HQ+ A

   

   Low

32

1.4

4.3

   Medium

231

10.5

4.5

   High

2780

69.9

2.5

HPV16 HQ+ B

   

   Low

35

1.3

3.7

   Medium

247

12.5

5.1

   High

2953

69.6

2.4

HPV18 HQ+ A

   

   Low

9

0.7

7.6

   Medium

18

0.8

4.1

   High

146

7.0

4.8

HPV18 HQ+ B

   

   Low

11

0.5

4.6

   Medium

21

1.1

5.5

   High

158

8.4

5.3

RLU/CO relative light units/cutoff, SD standard deviation, CV coefficient of variation, HQ+ A Novaprep® HQ+ medium without DTT, HQ + B Novaprep® HQ+ medium with DTT

Table 2

Reproducibility analysis of HPV16 DNA by hc2 using 3 batches of medium A and B

Batches

HQ+ A1

HQ+ A2

HQ+ A3

HQ+ B1

HQ+ B2

HQ+ B3

Mean (each series)

27

27

29

30

29

29

Mean all series

 

28

  

29

 

SD all series

 

1.7

  

2.4

 

CV%

 

6

  

8

 

Abbreviations as in Table 1

For method comparison, the ability of the hc2 test to assign the sample status without error was assessed from HPV16 positive and HPV negative cells diluted in HQ + A and HQ + B media in comparison with cells diluted in the STM reference medium. As shown in Table 3, all HPV16 positive samples gave a RLU/CO > 1 and all HPV negative samples gave a RLU/CO < 1, regardless of the medium. Accordingly, the sensitivity and specificity of the hc2 test for hrHPV DNA detection from cells diluted in HQ + A and HQ + B media were 100 %, as was the case for cells diluted in STM. Furthermore, the non-parametric Friedman test showed that the RLU/CO values given by HPV positive samples did not differ according to the medium used to collect cells.
Table 3

Method comparison

  

hc2

 
 

Pos

Neg

Total

STM pos

12

0

12

STM neg

0

12

12

total

12

12

 

HQ+ A pos

12

0

12

HQ+ A nega

0

11

11

total

12

11

 

HQ+ B pos

12

0

12

HQ+ B neg

0

12

12

total

12

12

 
 

Se

Sp

STM

100

100

HQ+ A

100

100

HQ+ B

100

100

Pos positive, Neg negative

aOne missing sample due to error in distribution

Se sensitivity, Sp specificity

HQ+ A Novaprep® HQ+ medium without DTT, HQ + B Novaprep® HQ+ medium with DTT

hrHPV DNA stability was tested at four different temperatures, two of which corresponded to worst-case conditions (between -15 to -30 and +40 °C). As shown in Table 4, the RLU/CO values given by the hc2 test were very similar over the entire duration of the experiment, irrespective of the medium, batch and storage temperature. We observed slightly lower RLU/CO values for cells collected in the medium with DTT and stored at 4 °C than for other conditions.
Table 4

Stability of samples diluted in media A and B

 

RLU/CO

 

18 °C to 25 °C

2 °C to 8 °C

40 °C

-15 °C to -30 °C

Weeks

A1

A2

A3

B1

B2

B3

A1

A2

A3

B1

B2

B3

A1

A2

A3

B1

B2

B3

A1

A2

A3

B1

B2

B3

0

41

42

36

37

37

39

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

51

48

45

36

47

62

49

52

48

36

41

41

51

67

51

48

59

48

52

46

46

48

50

48

4

51

42

47

44

46

53

54

49

44

36

45

43

53

54

50

49

39

43

47

45

48

49

57

50

6

49

51

46

46

46

50

53

52

52

31

35

35

47

44

52

45

49

45

-

-

-

-

-

-

8

51

54

50

41

50

43

48

55

40

35

38

32

54

49

55

40

46

52

-

-

-

-

-

-

10

41

41

42

38

36

38

41

45

39

28

36

33

42

40

42

40

42

38

-

-

-

-

-

-

12

45

42

43

35

40

47

49

40

46

29

33

29

50

47

47

37

43

42

-

-

-

-

-

-

16

48

52

50

42

43

33

49

51

47

34

31

36

49

48

42

44

47

42

-

-

-

-

-

-

24

34

33

33

33

29

31

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28

44

43

42

43

39

36

-

-

-

-

-

-

-

-

-

-

-

 

43

45

42

40

40

43

RLU/CO relative light units/cutoff

Among the 322 cytology samples from women with atypical squamous cells of undetermined significance (ASC-US), 204 were hrHPV positive and 118 were hrHPV negative.

Discussion

Accreditation of medical laboratories according to ISO 15189 standards is becoming a requirement for medical laboratories throughout Europe [12]. This implies that laboratory procedures, which include the preanalytical steps, must be validated and verified before applied for clinical testing, in order to ensure reliable results. Indeed, evaluations of biological tests, independently from the manufacturers, are crucial to choose the most appropriate test [13].

According to the manufacturer, the hc2 test has CE In Vitro Diagnostics (IVD) certification for cell samples harvested in 3 media, namely STM (Qiagen), PreservCyt (Hologic) and SurePath (BD). Some studies have reported the potential use of cell samples processed with different liquid-based cytology media for hrHPV testing by hc2 [11, 1417]. We report here that the performance characteristics of the hc2 assay are appropriate for its intended use with cells stored in the new Novaprep® HQ+ medium with or without DTT. Thus, pretreatment of cervical smears with a mucolytic agent (DTT up to 0.03 %) to obtain single-cell suspensions does not alter the specimen for further hrHPV DNA testing by hc2. In the same way, the adjunct of glacial acetic acid (GAA) in LBC specimen to lyse red blood cells has been evaluated and studies confirmed that GAA pretreatment had no significant impact on analytical and clinical performance of HPV tests [1820].

To identify potential sources of variation and/or interference due only to fixatives, each series of experiments (repeatability, reproducibility, method comparison and stability) was conducted using unique batches of cells and hc2 kits from the same batch number.

The coefficients of variation of the hc2 test ranged from 2.4 to 7.6 % for repeatability and 6 to 8 % for reproducibility. Such CVs are very satisfactory. Indeed, they are lower than 25 %, the maximum CV value that may be allowed within each series of samples to validate the test in quality controls. Moreover, the CVs observed here are lower than the value obtained with our own internal quality control, namely 18 %.

The method comparison made it possible to assess the robustness of hrHPV DNA detection by hc2 with cell samples prepared with Novaprep® HQ+ orange with or without DTT, in comparison with cells samples prepared with STM. Again, the results were more than adequate. hrHPV detection was as efficient with cells diluted in the two Novaprep® HQ+ orange media (A and B) as with cells diluted in STM. Furthermore, no cell samples stored in Novaprep® HQ+ orange medium and known to be positive or negative for the target were misclassified (false positive or false negative) after hrHPV DNA testing with the hc2 test.

Ensuring the stability of cervical samples is mandatory, since HPV testing may be delayed. Indeed, screening algorithms recommend hrHPV DNA testing as a triage test for women with cytological abnormalities. This is the case in France, where reflex HPV is an option following ASC-US cytology. Furthermore, in some situations, samples must be shipped to a distant molecular biology laboratory in charge of hrHPV testing. The stability experiment conducted in this study demonstrates that both HQ + A and HQ + B media adequately preserve hrHPV DNA and allow for its efficient detection with hc2 up to 6 months at room temperature (18-25 °C), and up to 3 months in refrigerated conditions (+4 °C). Moreover, excellent stability was demonstrated in the two “worst-case” scenarios, namely samples stored betwen -15°C to -30°C for 6 months and at +40 °C for 3 months. The Novaprep® HQ+ orange media with or without DTT are particularly well adapted for countries with a tropical or equatorial climate, where air-conditioning may not be systematically available. In a practical point of view, the rate of hrHPV detection from cervical samples with ASC-US cytology stored in the Novaprep® HQ+ LBC medium was 63 %. This rate, similar to that published with ASC-US samples stored in SurePath media [21], indicates a good hrHPV DNA preservation.

The robustness of the Novaprep HQ+ medium for hrHPV DNA detection was also recently demonstrated with the real-time PCR based Cobas® 4800 HPV test [22]. Although the study by Khiri, as well as our own results, suggest that it would be possible to use cells collected in Novaprep® HQ+ orange medium for hrHPV DNA detection by molecular testing, this does not by any means exempt each individual laboratory from the need to verify/validate the method according to ISO15189 standards before using this medium in routine practice. Furthermore, Hortlund et al. suggested that the clinical sensitivity of HPV test should be annually assessed to warrant high quality results [23].

Conclusion

This study provides evidence that the Novaprep® HQ+ orange medium does not alter viral DNA preservation and does not render cell samples inadequate for hrHPV DNA testing with hc2.

Abbreviations

ASC-US, atypical squamous cells of undetermined significance; CV, coefficient of variation; DMEM, Dulbecco’s Modified Eagle Medium; DTT, dithiothreitol; EMEM, Eagle’s Minimal Essential Medium; FBS: Fetal Bovine Serum; GAA, glacial acetic acid; hc2, hybrid capture 2; HPV, human papillomavirus; hrHPV, high-risk human papillomavirus; HSIL, high grade squamous intraepithelial lesion; LBC, liquid-based cytology; RLU/CO, relative light units/cutoff; RPMI, Roswell Park Memorial Institute medium; SD, standard deviation; STM, specimen transport medium

Declarations

Acknowledgements

We are indebted to Laurence Madoz and Evelyne Chézy for their excellent technical assistance with hc2 tests and to Alice Brunier-Baraquin for statistical analysis. The authors thank Fiona Ecarnot (EA3920, University Hospital Besancon, France) for editorial assistance.

Funding

The hc2 kits and Novaprep HQ+ orange media were provided by Novacyt. Part of this work was supported by grants from La Ligue Contre le Cancer (Comité du Doubs and CCIR-GE) and the Conseil Régional de Franche-Comté.

Availability of data and material

Data supporting our findings can be found in EA3181, Laboratoire de Biologie Cellulaire et Moléculaire, Centre Hospitalier Régional Universitaire, Boulevard A Fleming, 25030 Besançon cedex.

Authors’ contributions

CM, JLP conception and design of the work, SL, performed some experiments; DG, SL, CM, JLP analysis and interpretation of data; DG, JLP drafting of the manuscript; SL, DR, CM critical revision of the manuscript. All authors read and approved the final manuscript.

Competing interests

Grant from Novacyt to JLP.

Consent for publication

Not applicable.

Ethics approval and consent to participate

All samples were stored in a biobank approved by the local ethics committee (Comité de Protection des Personnes Est II), and for which a declaration of collection and storage of human samples for research use has been lodged with the French Ministry of Higher Education and Research (Ministère de l’Enseignement Supérieur et de la Recherche) (declaration number DC-2014-2086).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
COMUE UBFC, Univ Franche-Comte
(2)
CHRU Besancon
(3)
EA 3181, LabEx LipSTIC ANR-11-LABX-0021, FED4234
(4)
Inserm CIC 1431
(5)
Laboratoire de Biologie Cellulaire et Moléculaire, Centre Hospitalier Régional Universitaire

References

  1. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111:167–77.View ArticlePubMedGoogle Scholar
  2. Solomon D, Schiffman M, Tarone R, Group AS. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293–9.View ArticlePubMedGoogle Scholar
  3. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL, Canadian Cervical Cancer Screening Trial Study G. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579–88.View ArticlePubMedGoogle Scholar
  4. Riethmuller D, Ramanah R, Prétet JL, Mougin C. Integrating HPV testing for primary screening? J Gynecol Obstet Biol Reprod (Paris). 2008;37 Suppl 1:S139–151.View ArticleGoogle Scholar
  5. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J, New Technologies for Cervical Cancer screening Working G. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249–57.View ArticlePubMedGoogle Scholar
  6. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360:1385–94.View ArticlePubMedGoogle Scholar
  7. Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev Mol Diagn. 2008;8:599–605.View ArticlePubMedGoogle Scholar
  8. Popadiuk C, Gauvreau CL, Bhavsar M, Nadeau C, Asakawa K, Flanagan WM, Wolfson MC, Coldman AJ, Memon S, Fitzgerald N, Lacombe J, Miller AB. Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada. Curr Oncol. 2016;23:S56–63.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Bosch FX, Robles C, Diaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M, Petry KU, Poljak M, Kjaer SK, Meijer CJ, Garland SM, Salmeron J, Castellsague X, Bruni L, de Sanjose S, Cuzick J. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016;13:119–32.View ArticlePubMedGoogle Scholar
  10. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015;125:330–7.View ArticlePubMedGoogle Scholar
  11. Prétet JL, Vidal C, Le Bail CK, Ramanah R, Carcopino X, Cartier I, Labouyrie E, Kantelip B, Coumes-Marquet S, Riethmuller D, Mougin C. Novaprep((R)) Vial Test is a suitable liquid-based cytology medium for high risk human papillomavirus testing by Hybrid Capture 2. J Clin Virol. 2010;49:286–9.View ArticlePubMedGoogle Scholar
  12. Berwouts S, Morris MA, Dequeker E. Approaches to quality management and accreditation in a genetic testing laboratory. Eur J Hum Genet. 2010;18 Suppl 1:S1–19.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine. 2012;30 Suppl 5:F100–106.View ArticlePubMedGoogle Scholar
  14. Bergeron C, Cas F, Fagnani F, Didailler-Lambert F, Poveda JD. Human papillomavirus testing with a liquid-based system: feasibility and comparison with reference diagnoses. Acta Cytol. 2006;50:16–22.View ArticlePubMedGoogle Scholar
  15. Garbar C, Mascaux C, Fontaine V. Efficiency of an inexpensive liquid-based cytology performed by cytocentrifugations: a comparative study using the histology as reference standard. Cytojournal. 2005;2:15.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Hantz S, Goudard M, Marczuk V, Renaudie J, Dussartre C, Bakeland D, Denis F, Alain S. HPV detection and typing by INNO-LiPA assay on liquid cytology media Easyfix Labonord after extraction QIAamp DNA Blood Mini Kit Qiagen and Nuclisens easyMAG Biomerieux. Pathol Biol (Paris). 2010;58:179–83.View ArticleGoogle Scholar
  17. Leduc F, Bonniere M, Farre I, Staelen P. Human papillomavirus detection by the hybrid capture II assay with the liquid cell preservation solution Easyfix. Ann Biol Clin (Paris). 2004;62:687–90.Google Scholar
  18. McMenamin M, McKenna M. Stability of human papillomavirus (HPV) in cervical ThinPrep specimens previously lysed with glacial acetic acid: effect on cobas 4800 HPV test performance. Cancer Cytopathol. 2014;122:250–6.View ArticlePubMedGoogle Scholar
  19. Moore C, Duvall E, Braby E, Reid G, Docherty E, Grieve L, Cubie H, Graham C, Cuschieri K. Clinical sensitivity of HPV assays for the detection of high grade cervical disease in cervical samples treated with glacial acetic acid. J Clin Virol. 2016;79:32–5.View ArticlePubMedGoogle Scholar
  20. Moore C, Cuschieri K, McQueen F, Duvall E, Graham C, Cubie HA. Effect of glacial acetic acid pre-treatment of cervical liquid-based cytology specimens on the molecular detection of human papillomavirus. Cytopathology. 2013;24:314–20.PubMedGoogle Scholar
  21. Preisler S, Rebolj M, Untermann A, Ejegod DM, Lynge E, Rygaard C, Bonde J. Prevalence of human papillomavirus in 5072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. PLoS One. 2013;8:e59765.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Khiri H, Camus C, Portugal M, Penaranda G, Boyer S, Halfon P. Cytological and virological medium performance and stability assessment using the Cobas 4800 HPV test (Roche Diagnostics) used in France. Ann Biol Clin (Paris). 2014;72:213–23.Google Scholar
  23. Hortlund M, Sundstrom K, Lamin H, Hjerpe A, Dillner J. Laboratory audit as part of the quality assessment of a primary HPV-screening program. J Clin Virol. 2016;75:33–6.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016